Foresite Capital

Venture Capital

Healthcare-focused venture capital and growth equity firm investing in biotechnology, pharmaceuticals, diagnostics, and healthcare services.

Profile

Headquarters
San Francisco, US
Investments
4
Companies
2

Capital

Total Deployed
$1.0B
Lead Rounds
2
Website
www.foresitecapital.com

Portfolio

2 companies
Candid Therapeutics $875M
Private San Diego, California, United States

Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager antibodies to treat autoimmune and inflammatory diseases. The company's platform redirects T-cells to selectively eliminate autoreactive B-cells, with clinical programs spanning five autoimmune indications. Founded by Ken Song after his $4.1B sale of RayzeBio to Bristol Myers Squibb.
Pardes Biosciences $127M
Acquired Carlsbad, US

Clinical-stage biopharmaceutical company that developed novel oral antiviral therapeutics targeting COVID-19. Went public via SPAC merger in 2021 before being acquired by MediPacific (a Foresite Capital affiliate) in 2023 after its lead candidate failed Phase 2 trials.

Investment data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.